Elizabeth Masson-Hurlburt compensation by year
CorMedix Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Salary | $280,000 | $291,792 | $310,800 |
| Bonus | $0 | $0 | $37,800 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $298,504 | $332,420 | $742,910 |
| Non-equity incentive | $67,200 | $136,500 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $25,734 | $35,561 | $44,818 |
| Total | $671,438 | $796,273 | $1,136,328 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CorMedix Inc. DEF 14A filed August 30, 2022, accession 0001213900-22-052252, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CorMedix Inc. filed document, accession 0001213900-22-052252. Every figure is read from that document and cited to the page and table it appears in. Filed August 30, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 70,000 | — | $8.32 |
| Option | 9,300 | — | $1.45 |
| Option | 2,100 | — | $8.30 |
| Option | 12,382 | — | $5.63 |
| Option | 18,750 | — | $4.08 |
| Option | 18,750 | — | $5.63 |
| Option | 52,500 | — | $8.32 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CorMedix Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
35 Form 4 lines since the FY2021 proxy (filed August 30, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| — | — | — | — | — | 45,397 |
| 2026-08-29 | Tax withholding | — | 8,076 | $8.30 | 270,463 |
| 2026-02-04 | Grant or award | — | 36,006 | $0.00 | 278,539 |
| 2026-01-23 | Tax withholding | — | 10,778 | $7.27 | 242,533 |
| 2026-01-23 | Grant or award | — | 93,010 | $0.00 | 253,311 |
| 2026-01-12 | Tax withholding | — | 5,794 | $7.15 | 160,301 |
| 2026-01-02 | Tax withholding | — | 10,895 | $12.16 | 166,095 |
| 2025-09-11 | Exercise or conversion | — | 41,121 | $1.45 | 218,111 |
The 8 most recent of 35 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CorMedix’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Khoso Baluch | Former Chief Executive Officer | $2,596,173 |
| Thomas Nusbickel | Former Chief Commercial Officer | $1,876,582 |
| Phoebe Mounts | Executive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations | $1,613,097 |
| Matthew David | Executive Vice President and Chief Financial Officer | $1,423,302 |
| John Armstrong | Former Executive Vice President for Technical Operations | $1,339,348 |
| Elizabeth Masson-Hurlburt · this page | Executive Vice President and Head of Clinical Operations | $1,136,328 |
The full CorMedix compensation record
free company briefThis page is one person within CorMedix's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CorMedix's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.